English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 12.36 |
| Open | 12.3 |
| 1-Year Change | 84.68% |
| Day's Range | 12.3 - 12.57 |
Liquidia Corporation is a biopharmaceutical company that is focused on the development, manufacturing and commercialization of products, which address unmet patient needs with a focus directed towards the treatment of pulmonary hypertension (PH). The Company operates, through its wholly owned subsidiaries, Liquidia Technologies and Liquidia PAH. Liquidia Technologies has developed YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic treprostinil injection. Its United Therapeutics developed treprostinil under the brand name Remodulin. The Company’s PRINT engineering technology allows to engineer and manufacture uniform drug particles with control over the size, three-dimensional geometric shape and chemical composition of the particles. The Company operates from over 45,000 square foot facility in Morrisville, North Carolina.
BRIEF: For the fiscal year ended 31 December 2021, Liquidia Corp revenues increased from $740K to $12.9M. Net loss decreased 42% to $34.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balanc decrease of 40% to $18.6M (expense), Depr of Fin Lease R/O Use Assets in SGA decrease of 80% to $267K (expense).
